이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Zhongzhi Pharmaceutical Holdings 미래 성장

Future 기준 확인 0/6

현재 Zhongzhi Pharmaceutical Holdings 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장	10.7%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Jun 19

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Zhongzhi Pharmaceutical Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:3737 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2023	2,050	163	-70	102	N/A
9/30/2023	2,062	164	18	168	N/A
6/30/2023	2,074	164	106	234	N/A
3/31/2023	1,950	135	151	259	N/A
12/31/2022	1,826	106	195	285	N/A
9/30/2022	1,766	84	147	263	N/A
6/30/2022	1,706	63	98	242	N/A
3/31/2022	1,726	57	44	210	N/A
12/31/2021	1,747	52	-9	178	N/A
9/30/2021	1,750	93	-46	132	N/A
6/30/2021	1,753	133	-83	86	N/A
3/31/2021	1,678	136	-54	90	N/A
12/31/2020	1,604	139	-25	93	N/A
9/30/2020	1,524	133	29	120	N/A
6/30/2020	1,444	128	82	147	N/A
3/31/2020	1,393	121	92	157	N/A
12/31/2019	1,342	115	102	168	N/A
9/30/2019	1,282	106	88	160	N/A
6/30/2019	1,221	97	75	152	N/A
3/31/2019	1,182	91	39	116	N/A
12/31/2018	1,142	85	4	80	N/A
9/30/2018	1,106	82	-15	55	N/A
6/30/2018	1,070	79	-35	29	N/A
3/31/2018	1,007	74	-19	40	N/A
12/31/2017	945	70	-2	51	N/A
9/30/2017	874	65	N/A	52	N/A
6/30/2017	803	60	N/A	53	N/A
3/31/2017	767	57	N/A	51	N/A
12/31/2016	730	54	N/A	49	N/A
9/30/2016	715	52	N/A	41	N/A
6/30/2016	700	50	N/A	34	N/A
3/31/2016	694	65	N/A	45	N/A
12/31/2015	688	81	N/A	56	N/A
9/30/2015	671	91	N/A	80	N/A
6/30/2015	655	101	N/A	104	N/A
3/31/2015	625	94	N/A	113	N/A
12/31/2014	596	87	N/A	122	N/A
12/31/2013	483	38	N/A	45	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 3737 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 3737 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 3737 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 3737 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 3737 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 3737 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Zhongzhi Pharmaceutical Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Recent updates

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Now 20% undervalued after recent price drop

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend

Upcoming dividend of HK$0.03 per share

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 17, 2024

Chairman recently bought HK$4.0m worth of stock

Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in FY 2022)

Final dividend of HK$0.03 announced

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Chairman recently bought HK$1.4m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Chairman recently bought HK$467k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Chairman recently bought HK$135k worth of stock

Chairman recently bought HK$955k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023

Investor sentiment improves as stock rises 15%

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend

Upcoming dividend of HK$0.09 per share at 5.4% yield

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.062 in FY 2021)

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Deputy GM & Executive Director recently bought HK$229k worth of stock

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

First half 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.081 in 1H 2021)

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Chairman recently bought HK$177k worth of stock

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Chairman recently bought HK$448k worth of stock

Less than half of directors are independent

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Chairman recently bought HK$925k worth of stock

Investor sentiment improved over the past week

Chairman recently bought HK$1.8m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.081 (vs CN¥0.086 in 1H 2020)

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: HK$1.76

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Upcoming Dividend of HK$0.051 Per Share

First half earnings released

First half earnings released

New 90-day high - HK$1.90

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 26, 2020